Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without BMS-986205 and intravesical BCG in BCG-unresponsive high-risk non-muscle invasive bladder cancer
NL-OMON55591Phase 2Completed
- Sponsor
- British Biotech
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, linrodostat and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) and Bladder cancer in situ (CIS) (4 arms), sponsored by British Biotech. Primary endpoints: Complete response rate, Duration of complete response and 1 more. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON55591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55591.